TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23201982
Drug: Pre-treatment stool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment stool samples analysis
Study: 17577027
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF)
Study: 15464665
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of reteplase plus abciximab
Study: 49746
Drug: 95% ethanol
Normalized name: ALCOHOL 95 mL in 100 mL TOPICAL SOLUTION [95% Ethanol (190 Proof)]
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 95% ethanol solution containing 0‐5% chlorhexidine digluconate applied with a gloved hand for two minutes
Study: 49746
Drug: Aqueous solution
Normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous solution of chlorhexidine applied with a gloved hand
Study: 49746
Drug: 70% alcoholic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70% alcoholic solution of chlorhexidine applied with a gloved hand
Study: 28478975
Drug: Adalimumab 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 0.4 mg/kg
Study: 14672962
Drug: Carbohydrate (CHO)
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CHO) ingestion (10 ml x kg(‐1) x h(‐1) CHO (6%))
Study: 9273036
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg lidocaine applied topically to the muscle after opening the conjunctiva
Study: 29889137
Drug: Mebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebo ointment
Study: 29889137
Drug: Biafine cream
Normalized name: BIAFINE CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biafine cream
Study: 29141665
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) treatment for 6 months
Study: 26411014
Drug: Cranberry extract
Normalized name: CRANBERRY EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry extract 1 (36 mg of PACs)
Study: 26411014
Drug: Cranberry extract
Normalized name: CRANBERRY EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry extract 2 (36 mg of PACs)
Study: 26411014
Drug: Cranberry extract
Normalized name: CRANBERRY EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry extract 3 (36 mg of PACs)
Study: 12841798
Drug: Emulsion (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emulsion (75 mg/kg)
Study: 12841798
Drug: Emulsion (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emulsion (150 mg/kg)
Study: 12841798
Drug: Emulsion (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emulsion (300 mg/kg)
Study: 12841798
Drug: Emulsion (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emulsion (all doses)
Study: 8850404
Drug: Gabexate mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate mesilate (GM) 2 mg/kg/h in a central venous catheter
Study: 1626799
Drug: Allergen solution
Normalized name: catfish allergenic extract
DrugBank: Diphenylpyraline (DB01146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allergen solution
Study: 6203289
Drug: Colchicine 0.5
Normalized name: colchicine 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.5 mg X 3 daily for four weeks
Study: 31329184
Drug: Comprehensive anti-edematous
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive anti-edematous therapy (CAET)
Study: 31329184
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy with a conventional lymphovenous tonic and elastic compression (Control)
Study: 28786423
Drug: Lapatinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib treatment
Study: 28786423
Drug: Lapatinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib and taxane combination
Study: 26763145
Drug: medetomidine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: medetomidine (10 μg/kg)
Study: 26763145
Drug: medetomidine with
Normalized name: medetomidine
DrugBank: Medetomidine (DB11428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: medetomidine with MK-467 (250 μg/kg)
Study: 16269882
Drug: Neostigmine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 1.5 mg and Atropine 0.5 mg
Study: 12393766
Drug: Ropivacaine 5
Normalized name: fentanyl-ropivacaine 5 mcg/mL-0.1%-0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 5 mg ml(-1), 3.5 ml (17.5 mg)
Study: 12393766
Drug: Bupivacaine 5
Normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 5 mg ml(-1), 3.5 ml (17.5 mg)
Study: 9926189
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% 50 mg i.a. (group B)
Study: 7482412
Drug: 1-desamino-8-D-arginine vasopressin
Normalized name: 1-desamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-desamino-8-D-arginine vasopressin (DDAVP) infusion
Study: 528086
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving 500 ml dextran 70 during operation and again on the second postoperative day
Study: 30415629
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (cholecalciferol) at a dose of 2000 IU per day
Study: 21833551
Drug: L: -carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L: -carnitine supplementation and protein-restricted diet
Study: 17606725
Drug: Erlotinib (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (single agent)
Study: 12189358
Drug: Controlled-release flecainide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release flecainide acetate (100 mg/day)
Study: 12189358
Drug: Controlled-release flecainide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release flecainide acetate (200 mg/day)
Study: 12189358
Drug: Controlled-release flecainide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release flecainide acetate
Study: 12189358
Drug: Immediate-release flecainide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release flecainide acetate
Study: 678389
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg piretanide/day
Study: 678389
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg frusemide/day
Study: 678389
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg bumetanide/day
Study: 678389
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three diuretics
Study: 24362488
Drug: Ponesimod (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponesimod (10 mg)
Study: 31266149
Drug: Ponesimod (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponesimod (10 mg) with cenerimod (2 mg once daily) at near half steady-state (Day 18)
Study: 31266149
Drug: Ponesimod (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponesimod (10 mg) with cenerimod (2 mg once daily) at steady-state (Day 37)
Study: 31266149
Drug: Cenerimod (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenerimod (2 mg once daily)
Study: 27728839
Drug: Progressive resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive resistance plus balance training (PRBT) - six months of twice weekly machine-based, moderate to high intensity, supervised training followed by six months of unsupervised follow-up.
Study: 22580932
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (600,000 IU monthly for 8 weeks)
Study: 19750476
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 0.5% bupivacaine with 1:200,000 epinephrine
Study: 19750476
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of normal saline solution (placebo)
Study: 15872336
Drug: Peroral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peroral estrogen (PE) therapy
Study: 15872336
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen therapy
Study: 15872336
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy (combined)
Study: 10576182
Drug: Topical vaginal
Normalized name: emollients, topical vaginal gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vaginal 5-fluorouracil (5-FU) cream (2 g) for 6 months
Study: 10576182
Drug: Observation after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation after standard treatment for 6 months
Study: 1757615
Drug: 0.05% halobetasol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% halobetasol propionate cream
Study: 2434546
Drug: 0.05% clobetasol
Normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% clobetasol 17-propionate cream
Study: 6925983
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (surgery only)
Study: 9536449
Drug: Carbamazepine 300
Normalized name: carbamazepine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine 300 mg/day
Study: 31017556
Drug: Chicory seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chicory seed supplementation (infused 9 g/d)
Study: 31017556
Drug: Turmeric supplementation
Normalized name: Turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmeric supplementation (3 g/d)
Study: 31017556
Drug: Turmeric and
Normalized name: Turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmeric and chicory seed supplementation (3 g/d turmeric + infused 9 g/d chicory seed)
Study: 26779697
Drug: Lidocaine 1%
Normalized name: LIDOCAINE 1% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1% 1 mL subcutaneously
Study: 21946541
Drug: Morning dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosing of travoprost eye drops
Study: 21946541
Drug: Evening dosing
Normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dosing of travoprost eye drops
Study: 21946541
Drug: First month
Normalized name: Chantix First Month of Therapy Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: First month dosing of travoprost eye drops
Study: 21946541
Drug: Second month
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second month dosing of travoprost eye drops
Study: 21946541
Drug: Morning dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosing
Study: 21946541
Drug: Evening dosing
Normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dosing
Study: 21946541
Drug: Morning dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosing vs Evening dosing
Study: 19148042
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone (3 doses before incision, 8 hours, and 16 hours later)
Study: 19148042
Drug: Saline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (3 doses before incision, 8 hours, and 16 hours later)
Study: 14695867
Drug: Glucose Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose Insulin intervention (maintaining euglycaemia)
Study: 14695867
Drug: Admission plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Admission plasma glucose > or = 6.1 mmol/l and glycosylated haemoglobin > or = 6.2%
Study: 7809567
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bright light plus goggles
Study: 29808377
Drug: Fosaprepitant (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosaprepitant (150 mg intravenous single dose)
Study: 26176994
Drug: Alfentanil 56
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 56 μg/kg
Study: 26176994
Drug: Alfentanil doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil doses (0, 10, 20, 30, 40, 50, 60 μg/kg)
Study: 26176994
Drug: Thiopental 4
Normalized name: thiopental 400 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 4 mg/kg and Rocuronium 0.6 mg/kg
Study: 23357440
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT), 16 sessions of weekly therapy
Study: 16413556
Drug: Dunaliella capsules
Normalized name: DUNALIELLA SALINA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dunaliella capsules providing 60 mg beta-carotene/day (first trial)
Study: 16413556
Drug: Dunaliella capsules
Normalized name: DUNALIELLA SALINA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dunaliella capsules (second trial)
Study: 16413556
Drug: Dunaliella capsules
Normalized name: DUNALIELLA SALINA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dunaliella capsules (in mice)
Study: 16413556
Drug: Beta-carotene-deficient Dunaliella
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene-deficient Dunaliella capsules (second trial)
Study: 12883126
Drug: Sildenafil treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil treatment taken as required before sexual activity, up to two times per week
Study: 12883126
Drug: Changes in
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in sexual self-confidence and partner's wish to continue treatment
Study: 11052587
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg transdermal nicotine patches
Study: 1418071
Drug: Pirenzepine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (75 mg/d)
Study: 1418072
Drug: Pirenzepine (greater
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (greater than 75 mg/d)
Study: 29504820
Drug: Three-step reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-step reduction (TSR) therapy of integrated Chinese and Western Medicine
Study: 30738826
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of antihypertensive medication
Study: 26758532
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of antihypertensive medication
Study: 26758532
Drug: Complete discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete discontinuation of all antihypertensive medication
Study: 21897344
Drug: Oxiplex gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxiplex gel (treatment group)
Study: 19639351
Drug: Non-switchers (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-switchers (continued treatment with atorvastatin)
Study: 17604363
Drug: PEG‐IFN‐alpha‐2b (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN‐alpha‐2b (100 microg weekly) alone or in combination with lamivudine (100 mg daily)
Study: 15166128
Drug: Recombinant FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant FSH (rFSH) treatment
Study: 11488938
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (3000 microg retinol equivalent), iron (30 mg), and folate (400 microg)
Study: 11488938
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (iron (30 mg) and folate (400 microg))
Study: 8161479
Drug: Zofenopril calcium
Normalized name: zofenopril calcium
DrugBank: Zofenopril (DB13166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zofenopril calcium (7.5-30 mg twice a day)
Study: 2661184
Drug: Ipriflavone (Osteofix)
Normalized name: IPRIFLAVONE
DrugBank: Ipriflavone (DB13618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipriflavone (Osteofix) 600 mg/day for 6 months
Study: 30733029
Drug: ACL reconstruction
Normalized name: CONSTRICTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACL reconstruction and nonsurgical medial compartment treatment (Group 2, n = 54)
Study: 26977029
Drug: TIVA (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIVA (total intravenous anaesthesia) with propofol and remifentanil
Study: 26977029
Drug: CIIA (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIIA (combined intravenous and inhaled anaesthesia) with sevoflurane and remifentanil
Study: 22328192
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg modified-release metoclopramide tablet every 24 h
Study: 22328192
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg immediate-release metoclopramide tablet every 8 h
Study: 22328192
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg modified-release metoclopramide tablet
Study: 22328192
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg immediate-release metoclopramide tablet
Study: 19760415
Drug: I-131 under
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-131 under rhTSH stimulus after 4-day L-T4 withdrawal
Study: 19760415
Drug: I-131 under
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-131 under rhTSH stimulus after furosemide (25 mg/day for 3 days) and 4-day L-T4 withdrawal
Study: 19760415
Drug: I-131 under
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-131 under rhTSH stimulus after furosemide (25 mg/day for 3 days) and lithium (450 mg/day for 3 days) following 4-day L-T4 withdrawal
Study: 19760415
Drug: I-131 30
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-131 30 mCi under rhTSH stimulus without L-T4 withdrawal (control group)
Study: 17430318
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dopexamine and enteral nutrition
Study: 11994327
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose (LD) GH replacement therapy (3 microg/kg/day for 3 months, then 6 microg/kg/day for 3 months)
Study: 11994327
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose (LD) GH replacement therapy
Study: 11994327
Drug: Conventional Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Dose (CD) GH replacement therapy (6 microg/kg/day for 3 months, then 12 microg/kg/day for 3 months)
Study: 11994327
Drug: Conventional Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Dose (CD) GH replacement therapy
Study: 11692352
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% with noradrenaline 1:50,000 and vasopressin 0.25 IU/mL, and midazolam sedation
Study: 7483798
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A - three doses of 20 micrograms i.m. (n = 103)
Study: 7483798
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B - first dose i.d. (2 micrograms), second and third doses i.m. (20 micrograms) (n = 97)
Study: 7483798
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C - first and second doses i.d. (2 micrograms), third dose i.m. (20 micrograms) (n = 100)
Study: 29903093
Drug: BP 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BP 200 μmol/L
Study: 29903093
Drug: BP 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: BP 400 μmol/L
Study: 29903093
Drug: BP 800
Normalized name: Peptimax 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: BP 800 μmol/L
Study: 25552576
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (40 to 60 minutes, 3 times weekly for 6 months)
Study: 22057944
Drug: Methylprednisolone acetate
Normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone acetate (40 mg, 1 ml)
Study: 22057944
Drug: Betametazone disodium
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betametazone disodium phosphate (3 mg, 1 ml)
Study: 22057944
Drug: Triamsinolon acetonate
Normalized name: Acetone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamsinolon acetonate (40 mg, 1 ml)
Study: 22057944
Drug: Serum physiological
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum physiological (0.09% NaCl, 1 ml)
Study: 19421791
Drug: Aceclofenac (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aceclofenac (100 mg) - Tizanidine (2 mg) b.i.d for 7 days
Study: 19421791
Drug: Aceclofenac (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aceclofenac (100 mg) alone b.i.d for 7 days
Study: 7616869
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg/day continuously
Study: 7616869
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens 0.625 mg/day combined with medroxyprogesterone acetate 5 mg/day sequentially
Study: 7001490
Drug: pyritinol (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: pyritinol (800 mg daily)
Study: 31141728
Drug: Sequential DL‐PDT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential DL‐PDT plus IM
Study: 17542150
Drug: Apricitabine (ATC)
Normalized name: Emtricitabine
DrugBank: Apricitabine (DB12855)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apricitabine (ATC) 1,200 mg/day
Study: 17542150
Drug: Apricitabine (ATC)
Normalized name: Emtricitabine
DrugBank: Apricitabine (DB12855)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apricitabine (ATC) 1,600 mg/day
Study: 15581204
Drug: Mycobacterium vaccae
Normalized name: Mycobacterium vaccae
DrugBank: Mycobacterium vaccae (DB18449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycobacterium vaccae (SRL172) immunotherapy
Study: 8636652
Drug: L-glutamine, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-glutamine, 4 gm swish and swallow twice a day, from day 1 of chemotherapy for 28 days or for 4 days past the resolution of any post-chemotherapy mucositis